Thomson Reuters Foundation

Inform - Connect - Empower

Ameridose plans voluntary shutdown amid meningitis outbreak

Source: Thomson Reuters Foundation - Wed, 10 Oct 2012 21:34 GMT
Author: Reuters
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

(Adds details on shutdown at Ameridose, Alaunus)

By Tim McLaughlin

BOSTON, Oct 10 (Reuters) - Two Boston-area pharmacy companies that share common ownership with the company at the center of a deadly U.S. meningitis outbreak plan to cease operations temporarily as a precautionary move, Massachusetts health officials said on Wednesday.

Ameridose LLC, a private company that mixes drugs for hospitals nationwide, is expected to shut down for a week. Alaunus Pharmaceutical also will temporarily cease distribution of all products made by Ameridose or any other company under shared ownership.

State regulators said at a press conference they have no evidence to suggest that Ameridose products have been compromised and a recall has not been requested. Healthcare providers may continue to use any medications they have in stock.

Massachusetts regulators, meanwhile, are requiring all state compounding pharmacies to sign a statement that they are following rules on altering medications.

Ameridose, based in Westborough, Massachusetts, is working to distance itself from New England Compounding Center, which distributed thousands of vials of a contaminated steroid that has been implicated in 12 deaths.

All three companies - Alaunus, Ameridose and NECC - are owned by Gregory Conigliaro, an engineer who invented a way to turn plastic into pothole filler, and his brother-in-law, Barry Cadden, a pharmacist in charge of pharmacy operations at the New England Compounding Center, according to records filed with Massachusetts authorities. (Reporting By Tim McLaughlin; Additional reporting by Toni Clarke in Boston; Editing by Sandra Maler and Eric Walsh)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus